相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function
Camilo Rojas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus)
Bart C. De Jonghe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2009)
Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting Focus on Recent Developments
Rudolph M. Navari
DRUGS (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito et al.
LANCET ONCOLOGY (2009)
Palonosetron (AloxiA®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy
Maurizio Musso et al.
SUPPORTIVE CARE IN CANCER (2009)
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
Zhaocai Yu et al.
SUPPORTIVE CARE IN CANCER (2009)
Palonosetron in Prevention of Nausea and Vomiting After Highly Emetogenic Chemotherapy Before Haematopoietic Stem Cell Transplantation-Single Center Experience
P. Rzepecki et al.
TRANSPLANTATION PROCEEDINGS (2009)
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor
Camilo Rojas et al.
ANESTHESIA AND ANALGESIA (2008)
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
Rudolph M. Navari et al.
SUPPORTIVE CARE IN CANCER (2007)
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
Lawrence H. Einhorn et al.
SUPPORTIVE CARE IN CANCER (2007)
Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
Lorenzo Cohen et al.
SUPPORTIVE CARE IN CANCER (2007)
High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo
J. Morganrothi et al.
EJC SUPPLEMENTS (2007)
Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects
Ajit Shah et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2006)
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Mark G. Kris et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial
JT Hickok et al.
LANCET ONCOLOGY (2005)
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
RM Navari et al.
SUPPORTIVE CARE IN CANCER (2005)
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? - Systematic re-evaluation of clinical evidence and drug cost implications
O Geling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Delayed emesis: moderately emetogenic chemotherapy
F Roila et al.
SUPPORTIVE CARE IN CANCER (2005)
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update
SM Grunberg et al.
SUPPORTIVE CARE IN CANCER (2005)
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study
P Eisenberg et al.
ANNALS OF ONCOLOGY (2004)
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics - Perception versus reality
SM Grunberg et al.
CANCER (2004)
Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects
R Stoltz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron
P Eisenberg et al.
CANCER (2003)
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
R Gralla et al.
ANNALS OF ONCOLOGY (2003)
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists
RM Navari et al.
ANNALS OF PHARMACOTHERAPY (2003)
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics - A University of Rochester James P. Wilmot Cancer Center community clinical oncology program study of 360 cancer patients treated in the community
JT Hickok et al.
CANCER (2003)
Tropisetron - An update of its use in the prevention of chemotherapy-induced nausea and vomiting
K Simpson et al.
DRUGS (2000)
分享论文
